A Delhi court has rejected the anticipatory bail plea of Vicky Ramancha, accused of supplying counterfeit Ozempic medicines to foreign companies, citing risks to public health and threats to India’s pharmaceutical reputation. The court observed that such offences have serious international ramifications and undermine public confidence in the justice system.

Key highlights

Case background

• Ozempic is used for Type-2 diabetes treatment and long-term weight management.

• The accused allegedly supplied fake Ozempic to multiple foreign firms.

• Case registered by Delhi Police Economic Offences Wing (EOW).

Court’s observations

• Allegations involve grave offences against public health and safety.

• International impact on India’s pharmaceutical credibility.

• Bail denial to prevent undermining public trust in justice.

Prosecution’s claims

• The accused was part of a transnational fraud causing losses of over USD 18.8 million.

• Created false impressions of legitimate supply chains and government ties.

• Used falsified certificates, allegedly notarised by Patiala House Courts, to gain trust.

International dimension

• US federal authorities issued subpoenas under potential violations of criminal laws.

• Complaints include importation of misbranded drugs.

The court’s decision reinforces the judiciary’s strict stance against counterfeit drug operations, particularly those with global implications, highlighting the need for strong enforcement to protect public health and India’s pharma reputation.